Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 227

1.

Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.

Sormani MP.

Mult Scler. 2019 Sep 3:1352458519845837. doi: 10.1177/1352458519845837. [Epub ahead of print] No abstract available.

PMID:
31478793
2.

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00776-7. [Epub ahead of print]

PMID:
31452081
3.

The role of nutritional factors during adolescence in multiple sclerosis onset: a population-based incident case-control study.

Abdollahpour I, Sormani MP, Nedjat S, Mansournia MA, van der Mei I.

Nutr Neurosci. 2019 Jul 31:1-8. doi: 10.1080/1028415X.2019.1647689. [Epub ahead of print]

PMID:
31362644
4.

Single-Port Versus Conventional Laparoscopic Cholecystectomy: Better Cosmesis at the Price of an Increased Incisional Hernia Rate?

Casaccia M, Papadia FS, Palombo D, Di Domenico S, Sormani MP, Batistotti P, Mascherini M, De Cian F.

J Laparoendosc Adv Surg Tech A. 2019 Sep;29(9):1163-1167. doi: 10.1089/lap.2019.0374. Epub 2019 Jul 2.

PMID:
31264921
5.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

6.

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group.

J Neurol. 2019 Jun 17. doi: 10.1007/s00415-019-09424-8. [Epub ahead of print]

PMID:
31209573
7.

Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data.

Bovis F, Carmisciano L, Signori A, Pardini M, Steinerman JR, Li T, Tansy AP, Sormani MP.

BMC Med. 2019 Jun 18;17(1):113. doi: 10.1186/s12916-019-1345-2.

8.

Lifespan normative data on rates of brain volume changes.

Battaglini M, Gentile G, Luchetti L, Giorgio A, Vrenken H, Barkhof F, Cover KS, Bakshi R, Chu R, Sormani MP, Enzinger C, Ropele S, Ciccarelli O, Wheeler-Kingshott C, Yiannakas M, Filippi M, Rocca MA, Preziosa P, Gallo A, Bisecco A, Palace J, Kong Y, Horakova D, Vaneckova M, Gasperini C, Ruggieri S, De Stefano N; MAGNIMS Study Group.

Neurobiol Aging. 2019 Sep;81:30-37. doi: 10.1016/j.neurobiolaging.2019.05.010. Epub 2019 May 22.

PMID:
31207467
9.

Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.

Scarpazza C, Signori A, Cosottini M, Sormani MP, Gerevini S, Capra R.

Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162. [Epub ahead of print]

PMID:
31144589
10.

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.

Pellegrini F, Copetti M, Bovis F, Cheng D, Hyde R, de Moor C, Kieseier BC, Sormani MP.

Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513. [Epub ahead of print]

PMID:
31144577
11.

Different MRI patterns in MS worsening after stopping fingolimod.

Lapucci C, Baroncini D, Cellerino M, Boffa G, Callegari I, Pardini M, Novi G, Sormani MP, Mancardi GL, Ghezzi A, Zaffaroni M, Uccelli A, Inglese M, Roccatagliata L.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 16;6(4):e566. doi: 10.1212/NXI.0000000000000566. eCollection 2019 Jul.

12.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

13.

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

Waubant E, Banwell B, Wassmer E, Sormani MP, Amato MP, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T; IPMSSG.

Neurology. 2019 May 28;92(22):e2538-e2549. doi: 10.1212/WNL.0000000000007572. Epub 2019 May 1.

14.

Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.

Groppo E, Signori A, Sormani MP, Grosso C, Mantia L, Cattaneo D, Rovaris M.

Mult Scler J Exp Transl Clin. 2019 Apr 16;5(2):2055217319843673. doi: 10.1177/2055217319843673. eCollection 2019 Apr-Jun.

15.

Classification criteria for autoinflammatory recurrent fevers.

Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, Anton J, Arostegui JI, Barron K, Ben-Cherit E, Brogan PA, Cantarini L, Ceccherini I, De Benedetti F, Dedeoglu F, Demirkaya E, Frenkel J, Goldbach-Mansky R, Gul A, Hentgen V, Hoffman H, Kallinich T, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Laxer RM, Livneh A, Obici L, Ozen S, Rowczenio D, Russo R, Shinar Y, Simon A, Toplak N, Touitou I, Uziel Y, van Gijn M, Foell D, Garassino C, Kastner D, Martini A, Sormani MP, Ruperto N; Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2019 Aug;78(8):1025-1032. doi: 10.1136/annrheumdis-2019-215048. Epub 2019 Apr 24. Review.

PMID:
31018962
16.

Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI.

Treaba CA, Granberg TE, Sormani MP, Herranz E, Ouellette RA, Louapre C, Sloane JA, Kinkel RP, Mainero C.

Radiology. 2019 Jun;291(3):740-749. doi: 10.1148/radiol.2019181719. Epub 2019 Apr 9.

17.

Multiple sclerosis: clinical trial design 2019.

Pardini M, Cutter G, Sormani MP.

Curr Opin Neurol. 2019 Jun;32(3):358-364. doi: 10.1097/WCO.0000000000000697.

PMID:
30950845
18.

How much do periventricular lesions assist in distinguishing migraine with aura from CIS?

Lapucci C, Saitta L, Bommarito G, Sormani MP, Pardini M, Bonzano L, Mancardi GL, Gasperini C, Giorgio A, Inglese M, De Stefano N, Roccatagliata L.

Neurology. 2019 Apr 9;92(15):e1739-e1744. doi: 10.1212/WNL.0000000000007266. Epub 2019 Mar 8.

PMID:
30850445
19.

Revised upper limb module for spinal muscular atrophy: 12 month changes.

Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, De Sanctis R, Main M, Mayhew A, Muni Lofra R, Dunaway Young S, Glanzman AM, Duong T, Pasternak A, Ramsey D, Darras B, Day JW, Finkel RS, De Vivo DC, Sormani MP, Bovis F, Straub V, Muntoni F, Pane M, Mercuri E; iSMAC Consortium Group.

Muscle Nerve. 2019 Apr;59(4):426-430. doi: 10.1002/mus.26419. Epub 2019 Feb 7.

PMID:
30677148
20.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

Supplemental Content

Loading ...
Support Center